A single intravenous infusion of lonvoguran ziclumeran reduces hereditary angioedema attack rates by 87% compared to placebo in a phase 3 trial.
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Moving in New England Journal of Medicine, bioRxiv, Blood, BMJ and Nature Reviews Cancer.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 6
Add Coagulation, Bradykinin, Polyphosphates, and Angioedema as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Coagulation, Bradykinin, Polyphosphates, and Angioedema
Newest first · last 60 days
FXI-targeting monoclonal antibodies amrecibart and cenvacibart inhibit intrinsic pathway-triggered coagulation without affecting extrinsic pathway in humans and primates.
- Open access
Add Coagulation, Bradykinin, Polyphosphates, and Angioedema as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6157
- medRxiv1716
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3